权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Remote observed dosing to improve Suboxone compliance in clinical practice

远程观察给药以提高临床实践中的 Suboxone 依从性

基本信息

批准号：
9982921
负责人：
KYLE Matthew KAMPMAN
金额：
$ 24.15万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9982921
关键词：
Abstinence Accounting Address Adherence Agonist American Attention Behavior Therapy Behavior monitoring Buprenorphine Cellular Phone Cessation of life Chronic Cognitive Communicable Diseases Communities Control Groups Counseling Data Dose Drug Screening Effectiveness Emergency department visit Evaluation Funding Goals HIV Health Health Services Accessibility Hepatitis B Hepatitis C Individual Intervention Logistics Matched Group Measures Medical Medication Management Methadone Methodology Monitor Moods Morbidity - disease rate Opioid Outcome Measure Outpatients Overdose Participant Patient Self-Report Patients Pennsylvania Pharmaceutical Preparations Physicians Physicians&apos Offices Private Practice Process Public Health Randomized Randomized Clinical Trials Records Regulation Relapse Risk Risk Behaviors Sampling Screening Result Secure Suboxone Surveys Telephone Testing Treatment outcome Universities Urine Visit Weight Gain Withdrawal addiction attentional control base behavioral pharmacology buprenorphine treatment clinical care clinical practice cost design effective therapy experimental group health disparity illicit drug use improved innovation medication compliance methadone treatment misuse of prescription only drugs opioid agonist therapy opioid mortality opioid use opioid use disorder overdose death overdose risk prescription opioid prescription pain reliever primary care setting primary outcome programs recruit secondary outcome side effect substance abuse treatment treatment program treatment research urinary

项目摘要

PROJECT SUMMARY Opioid Use Disorder (OUD) is a major public health problem. Although several effective treatments that mitigate withdrawal and promote abstinence have been developed and are widely used, physicians have expressed hesitation in prescribing them due to misuse and diversion. The most recent of these treatments, buprenorphine (Suboxone®), can be prescribed by physicians in private practice. While Suboxone® has a lower abuse liability and decreased risk of overdose than methadone, compliance is low and diversion is an ongoing problem. The goal of this project is to develop and test the preliminary efficacy of using remote compliance monitoring in buprenorphine (Suboxone®) treatment for OUD. To that end, 40 subjects with OUD will be recruited through the University of Pennsylvania's Treatment Research Center, an outpatient substance abuse treatment facility. All subjects will receive a smartphone (and data plan); buprenorphine (Suboxone®) (16 mg/day, adjusted as needed according to individual requirements); and counseling in the form of weekly Medication Management (MM) for 12 weeks. Participants will be randomized into one of two groups: remote compliance monitoring or an attention match group that mirrors current clinical care. Using an iterative process we propose to develop an innovative, low cost, and scalable platform physicians can easily integrate into their private practice. Findings from the study will be used to support an R01 application to test the use of remote compliance monitoring in a larger prescription opiate-dependent sample in clinical practices. This methodology has broad applications for increased compliance in office-based treatment for addiction and other chronic medical conditions.

项目总结